Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2015

View Archived Issues

Ferring acquires assets of orthopedic biomaterial developer BioSET

Propanc starts animal studies of proteolytic proenzymes for cancer

RepliCel Life Sciences submits clinical trial application for RCS-01

ZP-GA-1 shows similar PK characteristics to native glucagon

Marathon sells non-strategic products to focus on treatments for rare diseases

Merck Serono and Sysmex Inostics announce opening of liquid biopsy RAS biomarker testing center

Cyclenium Pharma and Fundacion Medina form drug discovery agreement

Xeris Pharmaceuticals presents comparative PK/PD study of G-Pump and GlucaGen

Plasma kallikrein inhibitors disclosed in Kalvista Pharmaceuticals patent

U. S. researchers develop recombinant N. meningitidis factor H binding proteins

Isis reports chemically modified ssASOs targeting ataxin-3

Galapagos patents CFTR modulators

Takeda patent reveals prokineticin PKR1 receptor antagonists

New orexin receptor antagonists disclosed by Merck & Co.

Saroglitazar reverses biochemical manifestations of metabolic syndrome

Nobelpharma launches Zanosar i.v. infusion in Japan

Axitinib shows activity against mutant BCR-ABL1 leukemia

Eisai's phase III trial of eribulin in soft tissue sarcoma meets primary endpoint

AstraZeneca and Orca Pharmaceuticals partner to discover ROR gamma inhibitors

Isis Pharmaceuticals announces phase I results for prekallikrein inhibitor for HAE

Phase I results indicate ALKS-7106 does not warrant further development

Neurotrope releases topline results from phase IIa trial of bryostatin 1 for Alzheimer's disease

First patient treated in trial of Renevia in HIV-associated lipoatrophy

Eisai reports results from phase II trial of lenvatinib in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...